Tsung-Kun Chang*†, Tzu-Chieh Yin‡§, Wei-Chih Su*†, Hsiang-Lin Tsai*¶, Ching-Wen Huang*¶, Yen-Cheng Chen*, Ching-Chun Li*, Po-Jung Chen*, Cheng-Jen Ma*§, Kuo-Hsiang Chuang#, Tian-Lu Cheng**, Jaw-Yuan Wang*†¶††‡‡§§
Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569
Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer
(mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed
from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin
reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients
undergoing irinotecan-based chemotherapy. We enrolled and randomized More >
Login
Register
